Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in multitargeted therapy for patients with solid tumours.

C Le Tourneau1, S Faivre, E Raymond

  • 1Service Inter-Hospitalier de Cancérologie Beaujon-Bichat, Hôpital Beaujon, 100, Boulevard du Général Leclerc, Clichy, France. christophe.le-tourneau@bjn.aphp.fr

Cancer Treatment Reviews
|November 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification.

ESMO real world data and digital oncology·2026
Same author

Core variables for real-world clinicogenomic data collection in precision oncology.

ESMO real world data and digital oncology·2026
Same author

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

ESMO open·2025
Same author

MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.

ESMO open·2025
Same author

Unravelling the role of environmentally realistic concentrations of titanium dioxide nanoparticles in altering gametogenesis and gonadal health of female Pacific oysters (Magallana gigas): a histopathological approach.

Aquatic toxicology (Amsterdam, Netherlands)·2025
Same author

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

ESMO open·2025
Same journal

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same journal

Treatment of breast cancer brain metastases in the era of novel drugs.

Cancer treatment reviews·2026
Same journal

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same journal

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Cancer treatment reviews·2026
Same journal

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Cancer treatment reviews·2026
Same journal

Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes.

Cancer treatment reviews·2026
See all related articles

Molecularly targeted therapies offer new ways to treat solid tumors by targeting specific proteins. Future research should focus on patient selection and combination therapies to maximize benefits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecularly targeted anticancer therapies are rationally designed to interact with specific proteins involved in tumor development and progression.
  • These targeted agents represent a significant advancement over traditional chemotherapy.

Purpose of the Study:

  • To review the rationale and clinical data (Phase II/III) for approved and emerging multitargeted agents in solid tumor treatment.
  • To discuss future challenges and strategies for optimizing the use of these agents.

Main Methods:

  • Review of published Phase I, II, and III clinical trial data for approved and investigational multitargeted agents.
  • Analysis of drug mechanisms of action and clinical efficacy in various solid tumor types.

Related Experiment Videos

Main Results:

  • Approved agents like imatinib, sunitinib, sorafenib, and dasatinib have shown efficacy in licensed indications and promise in other tumor types.
  • Emerging multitargeted agents demonstrate broad-spectrum activity in early-phase trials, though clinical relevance requires further validation.

Conclusions:

  • Multitargeted agents have advanced cancer treatment, with approved drugs showing significant clinical benefits.
  • Future efforts should focus on personalized medicine approaches, including patient selection, optimized dosing, and combination strategies to enhance therapeutic outcomes.